Cerus Corp. (CERS) has steadily built its reputation in the biomedical field through its commitment to blood safety. The company's flagship technology, the INTERCEPT Blood System, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. With applications across platelets, plasma, red blood cells, and cryoprecipitation, Cerus has positioned itself as a key player in advancing pathogen reduction technologies for hospitals and blood centers worldwide.
A recent development underscored this mission. On December 10, Cerus announced a group purchasing agreement with Blood Centers of America (BCA), the largest blood supply cooperative in the United States. BCA member centers produce roughly half of the nation's platelet and cryoprecipitate supply, making the agreement significant in scope.
For comments and feedback: editorial@rttnews.com